NexImmune, Inc. (NEXI)

NASDAQ: NEXI · IEX Real-Time Price · USD
1.16
-0.09 (-7.20%)
Aug 19, 2022 4:00 PM EDT - Market closed
-7.20%
Market Cap 28.02M
Revenue (ttm) n/a
Net Income (ttm) -57.38M
Shares Out 24.16M
EPS (ttm) -2.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 36,158
Open 1.21
Previous Close 1.25
Day's Range 1.16 - 1.21
52-Week Range 1.08 - 18.78
Beta n/a
Analysts Buy
Price Target 3.57 (+207.8%)
Earnings Date Aug 8, 2022

About NEXI

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that ... [Read more...]

Industry Biotechnology
IPO Date Feb 12, 2021
Employees 74
Stock Exchange NASDAQ
Ticker Symbol NEXI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for NEXI stock is "Buy." The 12-month stock price forecast is 3.57, which is an increase of 207.76% from the latest price.

Price Target
$3.57
(207.76% upside)
Analyst Consensus: Buy
Stock Forecasts

News

NexImmune Reports Second Quarter 2022 Financial Results and Highlights FDA Clearance of IND for NEXI-003 for the Trea...

GAITHERSBURG, Md., Aug. 15, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...

NexImmune (NEXI) IND Gets Clearance for HPV-Related Cancer Drug

NexImmune (NEXI) gets FDA clearance for IND for drug for human papillomavirus (HPV)-related cancers.

Why Is NexImmune (NEXI) Stock Up 30% Today?

NexImmune appears to be making headway in the company's ongoing battle against HPV-related cancers -- and NEXI stock is heading higher today. The post Why Is NexImmune (NEXI) Stock Up 30% Today?

NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers

GAITHERSBURG, Md., July 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...

What Makes NexImmune, Inc. (NEXI) a New Buy Stock

NexImmune, Inc. (NEXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

NexImmune Reports First Quarter 2022 Financial Results and Provides Business Updates

GAITHERSBURG, Md., May 12, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted...

NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes

GAITHERSBURG, Md., May 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), Yale and JDRF have begun a two-year project to explore the use of NexImmune's AIM nanoparticles in combination with an...

NexImmune Announces Appointment of Dr. Leena Gandhi to its Board of Directors

GAITHERSBURG, Md., May 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted...

NexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center's Herbert Irvin...

GAITHERSBURG, Md., April 26, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a target...

NexImmune Promotes Mathias Oelke, Ph.D., To Chief Scientific Officer

Dr. Oelke is a scientific co-founder of NexImmune and a pioneer in the field of artificial antigen presenting cell (aAPC) technology Dr. Oelke is a scientific co-founder of NexImmune and a pioneer in th...

Executives Buy More Than $1M Of 5 Penny Stocks

The Dow Jones jumped around 200 points on Tuesday. Investors, meanwhile, focused on some notable insider trades.

Other symbols: PFMTRIBTTNXP

Insiders Buying These 5 Penny Stocks

The Dow Jones surged around 350 points on Thursday. Investors, meanwhile, focused on some notable insider trades.

Other symbols: LVONNRCATSSKN

NexImmune, Zephyr Join Forces For Oncology Target Discovery, Validation

NexImmune Inc (NASDAQ: NEXI) and Zephyr AI have announced a strategic partnership focusing on discovering and validating novel targets for new T-cell-mediated therapies in oncology.  The collaboration w...

NexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and Validation

GAITHERSBURG, Md., March 17, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) and Zephyr AI (Zephyr) today announced a strategic partnership focusing on the discovery and validation of novel targ...

NexImmune Announces Melanoma Research Collaboration with NYU Langone's Perlmutter Cancer Center

GAITHERSBURG, MD, March 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...

NexImmune to Present at the Barclays 2022 Global Healthcare Conference

GAITHERSBURG, Md., March 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a target...

NexImmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

GAITHERSBURG, Md., March 09, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a target...

NexImmune Appoints Kristi Jones as Chief Executive Officer and Member of the Board of Directors

Ms. Jones, a veteran of the biotechnology and pharmaceutical industries, has served as an Executive Officer of NexImmune since 2017 Ms. Jones, a veteran of the biotechnology and pharmaceutical industrie...

NexImmune Announces Research Collaboration with Rutgers, The State University of New Jersey, Related to Neuroendocrin...

GAITHERSBURG, Md., Feb. 01, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...

NexImmune to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel on “Expandi...

GAITHERSBURG, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...

NexImmune Announces Formation of Autoimmune and Infectious Diseases Scientific Advisory Board

GAITHERSBURG, Md., Jan. 05, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...

NexImmune Announces Preliminary Phase 1/2 NEXI-002 Results in Patients with Multiple Myeloma

GAITHERSBURG, Md., Dec. 12, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...

NexImmune Reports Third Quarter 2021 Financial Results and Provides Business Updates

GAITHERSBURG, Md., Nov. 12, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...

NexImmune to Announce Third Quarter 2021 Financial Results and Provide Corporate Update on November 12, 2021

GAITHERSBURG, Md., Nov. 08, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...

NexImmune to Present at The Society for Immunotherapy of Cancer 36th Anniversary Annual Meeting

GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...